LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

DexCom Inc

Fechado

SetorSaúde

69.73 1.19

Visão Geral

Variação de preço das ações

24h

Atual

Mín

68.85

Máximo

71.01

Indicadores-chave

By Trading Economics

Rendimento

-68M

200M

Vendas

-68M

1.2B

P/E

Médio do Setor

29.644

50.958

EPS

0.56

Margem de lucro

16.738

Funcionários

11,000

EBITDA

-52M

337M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+19.86% upside

Dividendos

By Acuity

Próximos Ganhos

29 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3B

27B

Abertura anterior

68.54

Fecho anterior

69.73

Sentimento de Notícias

By Acuity

18%

82%

35 / 342 Ranking em Healthcare

DexCom Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Sobre DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat